Variant Synonymizer: Platform to identify mutations defined in different ways is available now!

VarSy

Over 2,000 gene–disease validation summaries are now available—no login required!

Browse Summaries

RASGRP3 and Systemic Lupus Erythematosus

RASGRP3 has emerged as a compelling susceptibility gene for systemic lupus erythematosus (SLE), with support from multiple large-scale genome‑wide association studies. Two independent GWAS analyses in Chinese Han and Caucasian populations have demonstrated significant associations between variants in this gene and SLE, involving over 1,000 probands in the discovery phase (PMID:19838193) and replication in cohorts exceeding 3,000 cases (PMID:23249952). The cumulative evidence across these studies classifies the gene‑disease association as strong, with consistent statistical signals and broad replication across ethnicities.

In terms of genetic evidence, the association is supported by robust case‑control designs rather than classical familial segregation. Although detailed segregation counts are not provided in the original studies, the genetic association reflects a cumulative burden across large cohorts. The genetic evidence is drawn from replication of risk variants in different ethnic groups, underscoring the role of RASGRP3 as a susceptibility locus in this complex trait. The observed odds ratios from these GWAS further lend support to the relevance of the association while maintaining the typical modest effect seen in polygenic disorders.

The reported variant, incorporated here for illustration, is a somatic alteration identified in functional studies: c.1924G>T (p.Asp642Tyr). This variant was observed in tissue samples from metastases of radioactive iodine‑refractory differentiated thyroid cancer and, though originally evaluated in an oncogenic context, the functional characterization provides insight into the biological role of RasGRP3. Functional assays demonstrated that this mutation enhances Akt pathway activation, which is mechanistically consistent with immune dysregulation and inflammatory pathways implicated in SLE. Such experimental findings bridge the gap between statistical associations and biological function.

Functional assessments further indicate that the mutant RasGRP3 protein decreases expression of key regulators such as the sodium iodide symporter, and its downstream effects include increased cellular proliferation and invasion. These experiments, carried out in relevant cell lines and supported by rescue studies using PI3K/Akt inhibitors (PMID:30323976), underscore a mechanistic link between RasGRP3 function and pathogenic processes relevant to SLE. Although these functional studies originate from research in thyroid cancer, the demonstrated activation of the Akt pathway is a relevant pathway in SLE pathogenesis as well.

Integrating both genetic and experimental lines of evidence, the role of RASGRP3 in SLE is supported by statistically robust associations and corroborated by biochemical data linking variant-induced pathway dysregulation with disease‐relevant cellular processes. While the genetic findings are derived from well‐powered GWAS with replication across populations, the experimental data provide moderate support for a functional impact of RasGRP3 variants. The overall evidence exceeds the minimum threshold for a strong gene‑disease association, although additional studies may further refine the precise molecular mechanisms.

Key take‑home sentence: The convergence of statistically robust GWAS data with functional studies on RasGRP3 underscores its clinical utility as a risk factor for SLE, paving the way for improved diagnostic stratification and therapeutic targeting.

References

  • Nature genetics • 2009 • Genome‑wide association study in a Chinese Han population identifies nine new susceptibility loci for systemic lupus erythematosus PMID:19838193
  • European journal of human genetics : EJHG • 2013 • Genes identified in Asian SLE GWASs are also associated with SLE in Caucasian populations PMID:23249952
  • American journal of cancer research • 2018 • A somatic mutation of RasGRP3 decreases Na+/I- symporter expression in metastases of radioactive iodine‑refractory thyroid cancer by stimulating the Akt signaling pathway PMID:30323976

Evidence Based Scoring (AI generated)

Gene–Disease Association

Strong

Association confirmed by two large independent GWAS studies with replication in multiple cohorts involving over 1,000 cases (PMID:19838193) and additional cohorts (PMID:23249952).

Genetic Evidence

Moderate

GWAS data consistently demonstrate significant association signals for RASGRP3 in SLE, although the effect sizes are modest as typical for complex traits.

Functional Evidence

Moderate

Functional studies show that the mutant RasGRP3, exemplified by c.1924G>T (p.Asp642Tyr), modulates the Akt pathway and related cellular functions, concordant with SLE pathogenesis (PMID:30323976).